Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• WaksAG, WinerEP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.1932330667505
   PubMed Web of Science ®Google Scholar
• SlamonDJ, GodolphinW, JonesLA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712. doi:10.1126/science.24701522470152
   PubMed Web of Science ®Google Scholar
• HanX, ShiY, MaL, et al. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3149 Chinese patients. Chin Med J (Engl). 2014;127:246–253.24438611
   PubMed Web of Science ®Google Scholar
• ErogluZ, TagawaT, SomloG. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist. 2014;19:135–150. doi:10.1634/theoncologist.2013-028324436312
   PubMed Web of Science ®Google Scholar
• SlamonDJ, Leyland-JonesB, ShakS, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM20010315344110111248153
   PubMed Web of Science ®Google Scholar
• GeyerCE, ForsterJ, LindquistD, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743. doi:10.1056/NEJMoa06432017192538
   PubMed Web of Science ®Google Scholar
• SwainSM, MilesD, KimSB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, Phase 3 study. Lancet Oncol. 2020;21:519–530. doi:10.1016/S1470-2045(19)30863-032171426
   PubMed Web of Science ®Google Scholar
• DierasV, MilesD, VermaS, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732–742. doi:10.1016/S1470-2045(17)30312-128526536
   PubMed Web of Science ®Google Scholar
• LoiblS, GianniL. HER2-positive breast cancer. Lancet. 2017;389:2415–2429. doi:10.1016/S0140-6736(16)32417-527939064
   PubMed Web of Science ®Google Scholar
• MaF, LiQ, ChenS, et al. Phase I Study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB Receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35:3105–3112. doi:10.1200/JCO.2016.69.617928498781
   PubMed Web of Science ®Google Scholar
• MaF, OuyangQ, LiW, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a Randomized, Phase II Study. J Clin Oncol. 2019;37:2610–2619. doi:10.1200/JCO.19.0010831430226
   PubMed Web of Science ®Google Scholar
• ZhuY, LiL, ZhangG, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1033–1034:117–127. doi:10.1016/j.jchromb.2016.08.009
   PubMed Web of Science ®Google Scholar
• JiangZ, YanM, HuX, et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: a randomized phase III study. J Clin Oncol. 2019;37:suppl.1001. doi:10.1200/JCO.2019.37.15_suppl.1001
   Web of Science ®Google Scholar
• GourdE. Pyrotinib versus lapatinib in HER2-positive breast cancer. Lancet Oncol. 2019;20(10):e562. doi:10.1016/S1470-2045(19)30568-631477452
   PubMed Web of Science ®Google Scholar
• CameronD, CaseyM, OlivaC, NewstatB, ImwalleB, GeyerCE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15:924–934. doi:10.1634/theoncologist.2009-018120736298
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, SchwedlerK, SchmidtM, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273–2281. doi:10.1016/j.ejca.2011.06.02121741829
   PubMed Web of Science ®Google Scholar
• OlsonEM, Abdel-RasoulM, MalyJ, WuCS, LinNU, ShapiroCL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24:1526–1533. doi:10.1093/annonc/mdt03623463626
   PubMed Web of Science ®Google Scholar
• BuonomoOC, CareddaE, PortarenaI, et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS One. 2017;12(9):e0184680. doi:10.1371/journal.pone.018468028922402
   PubMed Web of Science ®Google Scholar
• MehtaAI, BrufskyAM, SampsonJH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261–269. doi:10.1016/j.ctrv.2012.05.00622727691
   PubMed Web of Science ®Google Scholar
• HuangT, LuoX, WuB, et al. Pyrotinib enhances the radiosensitivity of HER2 overexpressing gastric and breast cancer cells. Oncol Rep. 2020;44:2634–2644. doi:10.3892/or.2020.782033125154
   PubMed Web of Science ®Google Scholar
• LiY, QiuY, LiH, et al. Pyrotinib combined with vinorelbine in HER2-positive metastatic breast cancer: a multicenter retrospective study. Front Oncol. 2021;11:664429. doi:10.3389/fonc.2021.66442933996589
   PubMed Web of Science ®Google Scholar
• XuB, YanM, MaF, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-633581774
   PubMed Web of Science ®Google Scholar